RT Journal Article
SR Electronic
T1 A pharmacoepidemiological study of myocarditis and pericarditis following mRNA COVID-19 vaccination in Europe
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.27.22275706
DO 10.1101/2022.05.27.22275706
A1 Joana Tome
A1 Logan T. Cowan
A1 Isaac Chun-Hai Fung
YR 2022
UL http://medrxiv.org/content/early/2022/05/28/2022.05.27.22275706.abstract
AB Objective To assess myocarditis and pericarditis reporting rate as adverse drug reactions (ADRs) for the messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccines authorized in Europe.Methods Data on myocarditis and pericarditis related to mRNA COVID-19 vaccines (period: January 1, 2021 - February 11, 2022) were collected from the EudraVigilance database and combined with the European Centre for Disease Prevention and Control’s (ECDC) vaccination tracker database. The reporting rate was expressed as 1 million individual vaccinated-days with a corresponding 95% confidence interval (CI), and an observed-to-expected (OE) analysis was performed to check if there was an excess risk for myocarditis or pericarditis following mRNA COVID-19 vaccination.Results The reporting rate of myocarditis per 1 million individual vaccinated-days in the study period was 17.27 (95% CI, 16.34-18.26) for the CX-024414 vaccine and 8.44 (95% CI, 8.18-8.70) for TOZINAMERAN vaccine. The reporting rate for pericarditis per 1 million individual vaccinated-days in the study period was 9.76 (95% CI, 9.06-10.51) for the CX-024414 vaccine and 5.79 (95% CI, 5.56-6.01) for TOZINAMERAN vaccine. The OE analysis showed that both vaccines produced a myocarditis standardized morbidity ratio (SMR) greater than 1, with the CX-024414 vaccine having a greater SMR than TOZINAMERAN. The SMR for pericarditis was greater than 1 when considering the lowest background incidence, but smaller than 1 when considering the highest background incidence.Conclusions Our results suggest an excess risk of myocarditis following the first dose of mRNA COVID-19 vaccine, but the relationship between pericarditis and mRNA COVID-19 vaccine remains unclear.What is already known on this topic Cases of myocarditis and pericarditis were identified following mRNA COVID-19 vaccination in Europe. This study needed to be done to quantify the elevated risk, if any, of myocarditis and pericarditis 28 days following Tozinameran and CX-024414 vaccination among Europeans.What this study adds This study identifies an excess risk of myocarditis following the first dose of mRNA COVID-19 vaccine, but not for pericarditis. When considering the lowest background incidence rate, the results showed a pericarditis’ SMR greater than 1, and when the highest background incidence was considered, TOZINAMERAN showed a smaller than 1 SMR.How this study might affect research, practice, or policy The study helps inform healthcare professionals and laypeople of the COVID-19 vaccination’s risks and benefits and, therefore, post-vaccination clinical practice.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Only publicly available data are used in this study. This study was determined by Georgia Southern University's Institution Review Board (IRB) (H20364) to be exempt from full review under the G8 exemption category (Non-human subjects determination): This project does not involve obtaining information about living individuals or does not have direct interaction or intervention with individuals or their personal data so is not defined as human subjects research under human subjects regulations. ECDC Data on COVID-19 vaccination in the EU/EEA. Available at: https://www.ecdc.europa.eu/en/publications-data/data-covid-19-vaccination-eu-eea. Accessed 2/16/2022. EudraVigilance: European Database of suspected adverse drug reaction. European Medicines Agency. Available at: https://www.adrreports.eu/. Accessed 2/16/2022. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.ADRsadverse drug reactionsCIconfidence intervalCOVID-19coronavirus disease 2019ECDCEuropean Centre for Disease Prevention and ControlEEAEuropean Economic AreaEMAEuropean Medicines AgencyEUEuropean UnionmRNAmessenger ribonucleic acidOEobserved-to-expectedORodds ratioPRACPharmacovigilance Risk Assessment CommitteeRNAribonucleic acidSARS-CoV-2severe acute respiratory syndrome coronavirus 2SMRstandardized morbidity ratio